Search
Acamprosate
go.drugbank.com/drugs/DB00659ApprovedInvestigational[A229073] Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. … [L31758] Acamprosate is the first medication specifically formulated for the maintenance of alcohol abstinence in ethanol-dependent patients after alcohol detoxification[A997], unlike [naltrexone] and
Categories: Drugs Used in Addictive Disorders, Drugs Used in Alcohol DependenceSynonyms: N-Acetylhomotaurine, N-acetyl homotaurineAzficel-T
go.drugbank.com/drugs/DB11051ApprovedWithdrawnExpanded cells are then suspended in a cell medium. … As a replacement for lost dermal constituents in the aging or skin deformation process, treatment with autologous fibroblasts has shown to improve wrinkle and acne scar appearance than with placebo treatment
Doripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnThe FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications. … , resulting in a premature termination of the trial.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Powder for Injection 500mg, DORIBAX 500 MG (Doripenem) for InjectionDenosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigationalfor fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men with osteoporosis at high risk for fracture in September 2012. … [A263066] An Denosumab biosimilar, Jubbonti, was approved for Health Canada in February 2024.[L52083].
Categories: Drugs for Treatment of Bone DiseasesProducts: XGEVA 120mg Solution for Injection, XGEVA Solution for Injection 120 mg/vialGaradacimab
go.drugbank.com/drugs/DB15629Approved[L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema. … [L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan.
Categories: Drugs Used in Hereditary AngioedemaBordetella pertussis fimbriae 2/3 antigen
go.drugbank.com/drugs/DB10790ApprovedInvestigationalBordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct
Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, , Suspension for InjectionHypochlorite
go.drugbank.com/drugs/DB11123ApprovedInvestigationalHypochlorite is often used as a chemical reagent for chlorination and oxidation reactions. … Being unstable in the pure form, hypochlorite is most commonly used for bleaching, disinfectation, and water treatment purposes in its salt form, sodium hypochlorite.
Categories: Compounds used in a research, industrial, or household settingProducts: NaOClean E-WaterTechnetium Tc-99m disofenin
go.drugbank.com/drugs/DB09164ApprovedWithdrawnTechnetium Tc-99m disofenin is a radiopharmaceutical agent used in hepatobiliary imaging for diagnostic purposes. … It is available as an intravenous injection in a preparation kit under the name Hepatolite.
Categories: Compounds used in a research, industrial, or household settingProducts: Kit for the Preparation of Technetium Tc99m DisofeninBelzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigational[L36105] Initially considered to be undruggable, a binding pocket was eventually discovered in the HIF-2α molecule which allowed for compounds to bind and inhibit these proteins. … [L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers.
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigational[A239249] No clinical trials have been performed to assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a prescriber's clinical experience. … [L38834] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients